Quick Answer
Zenas BioPharma, Inc. reported Diluted EPS of $8.44 per share (loss) for fiscal year 2025.
Zenas BioPharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.44 | +29.0% |
| 2024 | -$11.89 | +51.0% |
| 2023 | -$24.25 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.22 | +75.7% | +2.4% |
| June 30, 2025 | -$1.25 | +94.8% | -56.2% |
| March 31, 2025 | -$0.80 | +95.5% | +84.1% |
| September 30, 2024 | -$5.02 | -356.1% | +79.3% |
| June 30, 2024 | -$24.23 | — | -35.4% |
| March 31, 2024 | -$17.89 | — | -1012.8% |
| September 30, 2023 | $1.96 | — | — |
- Zenas BioPharma, Inc. showed an increase of +29.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Zenas BioPharma, Inc.’s diluted eps has grown by 65.2% (from $24.25 per share (loss) to $8.44 per share (loss)).
- The most recent figure is from Zenas BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: